Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Sep 29;22(3):306–316. doi: 10.5853/jos.2020.01886

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2020 Korean Stroke Society

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 1. — Web of end-stage renal disease (ESRD), atrial fibrillation (AF), and medications. Aspirin: Although data inconclusive, but it is somewhat in favor of lower risk of stroke and mortality but at increased risk of bleeding. Warfarin: Associated with increased risk of bleeding but inconclusive data on stroke risk reduction and mortality. Apixaban: Mortality with apixaban 5 mg lower as compared to apixaban 2.5 mg and warfarin; risk of bleeding lower with apixaban as compared to warfarin, risk of transient ischemic attack (TIA)/cerebrovascular accident (CVA) possibly lower with apixaban 5 mg as compared to apixaban 2.5 mg but not as compared with warfarin. Increased, ; Decreased, ; Inconclusive, ☆.

Inline graphic — Web of end-stage renal disease (ESRD), atrial fibrillation (AF), and medications. Aspirin: Although data inconclusive, but it is somewhat in favor of lower risk of stroke and mortality but at increased risk of bleeding. Warfarin: Associated with increased risk of bleeding but inconclusive data on stroke risk reduction and mortality. Apixaban: Mortality with apixaban 5 mg lower as compared to apixaban 2.5 mg and warfarin; risk of bleeding lower with apixaban as compared to warfarin, risk of transient ischemic attack (TIA)/cerebrovascular accident (CVA) possibly lower with apixaban 5 mg as compared to apixaban 2.5 mg but not as compared with warfarin. Increased, ; Decreased, ; Inconclusive, ☆.